Download PDFPDF
60 The ardvaarc study (altered rivaroxaban doses, vitamin-K anticoagulation & academic research consortium bleeding): real-world’ outcomes of patients who require anticoagulation following percutaneous coronary intervention (PCI)
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address